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Background: The purpose of this study was to evaluate the feasibility of utilizing an in-vitro, closed loop
hemodialysis system as a method to assess drug clearance. Secondarily, this study tested the influence of variables
(blood flow rate, dialysate flow rate, and type of filter) in the hemodialysis procedure on the clearance of
vancomycin and gentamicin.
Methods: An in-vitro, closed loop hemodialysis system was constructed. The vancomycin (30 mg/L) and gentamicin
(25 mg/L) were added to a simulated blood system (SBS). Four conditions (C1-C4) were tested by defining the filter
(Polyflux 170H or F180) and the blood and dialysate flow rates (BFR and DFR). All hemodialysis sessions were
3 hours in length and each condition was completed in duplicate. Dialysate effluent was collected in a 50 gallon
polyethylene drum. Samples were collected (in duplicate) from the SBS and the dialysate effluent at baseline and at
the end of the hemodialysis session. Samples were analyzed for vancomycin and gentamicin with an ultrahigh
performance liquid chromatography/tandem mass spectrometry method.
Results: A total of eight 3-hour hemodialysis sessions were conducted. For all tested conditions (C1-C4), vancomycin
was undetectable in the SBS at the end of dialysis. However, total vancomycin recovery in the dialysis effluent was
85±18%, suggesting that up to 15% may have adsorbed to the dialysis filter or tubing. Gentamicin clearance from
SBS was >98% in all tested conditions. Average gentamicin recovery in the dialysate effluent was 99±15%.
Conclusion: Both vancomycin and gentamicin were readily removed by high-flux hemodialysis under all conditions
studied. No significant differences in drug clearance were observed between conditions used in this in vitro study.
The clinical implications of changing these hemodialysis parameters are unknown.
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Pharmacokinetics are significantly altered during hemo-
dialysis and require directed studies in this setting in
order to guide drug dosing [1,2]. These clinical studies
provide valuable information but are limited since dialysis
variables (flow rates, filter selection, time on dialysis) may
or may not be standardized [3-11]. Studies can be
designed using one regimen with standardized blood flow* Correspondence: darren.grabe@acphs.edu
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unless otherwise stated.rates (BFR) and dialysate flow rates (DFR), similar
hemodialysis filters and similar convective (ultrafiltration)
flow rates (UFR). While this type of design reduces
variability and is desirable in a small sample size, it
may confine application of the results to that stated
hemodialysis prescription and thus the determined
pharmacokinetic parameters. Studies that do not
standardize the dialysis prescription lack clarity on
the potential influence of those variables on drug
clearance. A more comprehensive study to evaluate the
impact of a change in one or more of these parameters is
desirable but challenging to conduct in an in vivo design.
However, these studies may be feasible in a simulated
model of hemodialysis. While in vitro models of dialysisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tigated the influence of changing just one variable such as
the dialyzer [12,13].
This study was aimed at characterizing the clearance of
vancomycin and gentamicin and the influence of changes in
3 variables (BFR, DFR and hemodialysis filters) on clearance
in a closed loop in vitro dialysis system. It is hypothesized
that the clearance of vancomycin and gentamicin will




This was an in vitro pharmacokinetic study of two
antibiotics in a model of hemodialysis.
Description of model
A closed-loop fixed volume reservoir of a 5-L normal
saline solution (4750 mL reservoir +250 mL tubing
and dialysis membrane volume) was prepared for a
simulated blood system (SBS). The normal saline had
a pH of 5.0 and an osmolarity of 308 mOsmol/L.
Polyvinyl chloride tubing was used to create the SBS.
The supply lines were connected from the dialysate
supply [Acid (NaturaLyte Liquid Acid Concentrate
2 mEq/L potassium, 2.5 mEq/L calcium) and bicarbonate
powder (NaturaLyte; Fresenius)] to the filter and from the
filter into a 50 gallon plastic drum for collection of
the dialysate. The system was primed with 250 mL of
normal saline prior to initiation of the dialysis procedure
and maintained at 37°C.
Four different conditions were studied (Table 1): two
sets of BFR (400 mL/min and 500 mL/min) and DFR
(600 mL/min and 800 mL/min) were tested. Table 1 also
outlines the characteristics of the two hemodialysis
membranes that were used in the study [Polyflux 170H
(Gambro) and the Optiflux F180 (Fresenius)]. The UFR
was maintained at 300 mL/hr to approximate the net fluid
removal of one liter, to simulate a typical hemodialysis
prescription, and to minimize convective solute clearance.
A volumetric HD machine (model 2008H, Fresenius USA,
Walnut Creek, CA) was used to control the BFR, DFR
and UFR. Each hemodialysis session was conducted forTable 1 Dialysis conditions tested
Conditions Blood flow rate
(mL/min)
Dialysate flow rate (mL/min)
C1 400 600 Poly
C2 500 800 Poly
C3 400 600 Optiflux
C4 500 800 Optiflux
*Measured with bovine blood, Hematocrit = 32%, Protein 60 g/L, at 37°C.
+Measured with in vitro bovine, Hematocrit = 32%.3 hours with no interruption. The dialysate solution was
flushed counter-current to SBS within the dialysis
membrane at the end of the session to rinse out tubing.
Each HD procedure was conducted in duplicate.Sample preparation and collection
Vancomycin 150 mg and gentamicin 125 mg were injected
into the SBS to achieve final concentrations of 30 mg/L
and 25 mg/L, respectively. Samples (5 mL) were collected
from SBS and dialysate at 0 and 180 min (end of session).
All spent dialysate during the simulated HD session was
collected in a 50 gallon drum and mixed prior to sampling
(5 mL aliquot) for vancomycin and gentamicin. Collected
samples were labeled and stored at -70°C until analysis.
Collected samples were stored in Nalgene freezer vials and
shipped in dry ice for analysis.Sample analysis
Vancomycin and gentamicin concentrations in study
samples were simultaneously determined using an ultra-
high performance liquid chromatography/tandem mass
spectrometry (UHPLC-MS/MS) method with modifica-
tions of Li et al. [14] Briefly, 25 μL of sample was diluted
with 20 mM pentafluoropropionic acid (PFPA, 250 μL),
then injected (10 μL) directly onto the LC-MS/MS.
Separation was achieved using a Thermo Accela UHPLC
system with a Thermo Hypersil GOLD C18 (50 X
2.1 mm, 1.9 μm) column, and a 5 mM PFPA in water to
5 mM PFPA in acetonitrile gradient. Detection and
quantification of analytes was achieved with a Thermo
TSQ Quantum Ultra triple quadrupole mass spectrometer
via heated electrospray ionization in positive ionization
mode. Selective reaction monitoring was utilized to follow
precursor to product ion m/z transitions of 724➜144
for vancomycin, 450➜322 for gentamicin C1a, 464➜322
for gentamicin C2 +C2a, 478➜322 for gentamicin C1,
468➜163 for tobramycin (internal standard for gentamicin),
and 646➜290 for cefoperazone (internal standard for
vancomycin). The calibration curves for the analysis ranged
from 0.5 μg/mL (the lower limit of quantification) to
35.0 μg/mL for both analytes. The intra- and inter-day
precision and accuracy were ≤12%.Filter Filter characteristics
flux (Gambro) Surface area 1.7 m2; Wall thickness 50 microns; Inner
diameter 215 microns; Ultrafiltration coefficient 70*
flux (Gambro)
F180 (Fresenius) Surface area 1.8 m2; Wall thickness 40 microns; Inner
diameter 200 microns; Ultrafiltration coefficient 60+
F180 (Fresenius)
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The mean ± standard deviation (SD) vancomycin and
gentamicin concentrations were calculated for each
sample. The percent change in vancomycin and gentamicin
concentration from beginning to end of HD session and
absolute amount of vancomycin and gentamicin eliminated
were calculated. A mean loss of greater than 15%
from the SBS of the initial concentration was considered
as a clinically important loss of either vancomycin or
gentamicin. Drug recovery was estimated using the
following mass balance equation:
Drug recovery mgð Þ ¼ DFRð Þ tð Þ  CDf g  1000
DFR: Dialysis flow rate (mL/min).
t: Hemodialysis duration (minutes).
CD: The drug concentration in dialysate (μg/mL).
To calculate hemodialysis clearance (CLD) [15]:
CLD ¼ CD  VolDA t
CD: The drug concentration in dialysate (μg/mL).
Vol D: The total volume of dialysate collected during
the dialysis time (mL).
A: Average concentration of drug in plasma entering
the dialyzer (μg/mL).
t: Hemodialysis duration (minutes).
Dialysis sessions were conducted in the ANephRx
Core laboratory at the Albany College of Pharmacy and
Health Sciences. Vancomycin and gentamicin concentra-
tions were analyzed at the University of Pittsburgh.
Statistical analysis
Data are reported as mean ± standard deviation. Compari-
sons of filters intradialytic clearances were made using the
Student’s t-test except for the C3 condition (Polyflux
BFR 400 mL/min; DFR 600 mL/min) where UFR was
different (UFR = 250 mL/hr) from other conditions
(UFR = 300 mL/hr). All statistical tests were performed as
two-sided, and a P < 0.05 was considered significant.
Results
A total of eight 3-hour hemodialysis sessions were
conducted. Instillation of both vancomycin and gentami-
cin into the SBS system resulted in a clear solution. The
dialysate compartment also consisted of a clear solution.
There was no visual evidence of color change in the SBS
or dialysate compartments during the study period.
Table 2 outlines the drug concentrations at different
time intervals (pre- and post-dialysis session) in four
experimental conditions. Table 3 summarizes the quantity
of vancomycin and gentamicin recovered in dialysate after
a 3-hour dialysis session using the mass balance equation
and the two drugs’ hemodialytic clearances. The meanvancomycin hemodialysis clearances (mL/min) were 82.1,
53.3, 64.1 and 47.7 respectively for conditions through C1
to C4. The mean quantity recovered in dialysate was
142.6 ± 9.6 mg and was undetectable in the SBS at the end
of dialysis for all tested conditions (C1-C4), indicating
complete removal from the SBS compartment. The mean
gentamicin hemodialysis clearances (mL/min) were 58.2,
43.5, 56.7 and 40.6 respectively for C1 to C4. The mean
quantity recovered in dialysate was 135.7 ± 8.9 mg. Drug
recovery in the effluent was 85±18% for vancomycin and
99±15% for gentamicin. Vancomycin and gentamicin
clearances in C2 and C4 (BFR of 500 mL/min and DFR of
800 mL/min) were similar. Specifically, vancomycin
clearances with Polyflux and Optiflux filters were 53.3
and 47.7 mL/min, respectively (p = 0.3), and gentamicin
clearances were 43.5 and 40.6 mL/min, respectively
(p = 0.6). Vancomycin and gentamicin clearances were
also similar in C1 (BFR 400 mL/min and DFR
600 mL/min) and C2 (BFR 500 and DFR 800 ml/min)
in Optiflux filter. Vancomycin clearances were 82.1
and 53.3 ml/min, respectively (p = 0.4). Gentamicin
clearances in C1 and C2 were 58.2 and 43.5 ml/min,
respectively (p = 0.1).
Discussion
To our knowledge, this is the first study to investigate
the influence of changes in BFR, DFR, and two different
filters (Polyflux and Optiflux) on vancomycin and gentami-
cin clearance using an in-vitro closed loop dialysis system.
Interestingly, regardless of types of filter, the rate of BFR
and DFR, vancomycin was undetectable in the SBS at the
end of dialysis for all tested conditions (C1-C4), suggesting
the drug is readily cleared by contemporary hemodialysis.
Gentamicin also exhibited nearly complete removal.
However, gentamicin was consistently measured in the
post-dialysis SBS with the mean value of 0.52 ± 0.01ug/mL.
This was unexpected since the molecular weight of vanco-
mycin (1485.74 g/mol [16]) is larger than the molecular
weight of gentamicin C1 (477.6 g/mol [17]).
Eighty five percent (±18%) of vancomycin was recovered
in the dialysis effluent compared to 99±15% with gentami-
cin. Drug characteristics such as molecular size, steric hin-
drance, can affect the clearance, and the 15% difference
suggests that some vancomycin may have adsorbed to the
dialysis filter or tubing [18]. The contribution of ultrafiltra-
tion to the overall clearance of vancomycin and gentamicin
was unable to be ascertained since the ultrafiltration rate of
300 mL/hr was held constant. The UFR may affect
hemofiltration (drug elimination) [19] yet, it did not in
our study. A limitation of this study was the use of normal
saline instead of blood in the SBS and a one compartment
model. Additionally, filters were not evaluated to verify
and quantify vancomycin filter binding. The study results
cannot be used to predict drug pharmacokinetics and
Table 2 The concentration of vancomycin and gentamicin at different time interval in different conditions
Condition Filter Sol Time (min) BFR (mL/min) DFR (mL/min) Vanco (ug/mL) TG (ug/mL)
C1 Poly SBS 0 400 600 20.04 ± 0.86 26.65 ± 1.69
Poly SBS 180 400 600 BLQ 0.51 ± 0
Poly Dial 0 400 600 BLQ BLQ
Poly Dial 180 400 600 1.35 ± 0.41 1.31 ± 0.18
C2 Poly SBS 0 500 800 31.91 ± 2.5 35.93 ± 0.13
Poly SBS 180 500 800 BLQ 0.53 ± 0.02
Poly Dial 0 500 800 BLQ BLQ
Poly Dial 180 500 800 1.06 ± 0.05 0.99 ± 0
C3 Opt* SBS 0 400* 600* 23.74 ± 5.27 25.41 ± 3.47
Opt SBS 180 400 600 BLQ 0.52 ± 0.01
Opt Dial 0 400 600 BLQ BLQ
Opt Dial 180 400 600 1.20 ± 1 1.14 ± 0.93
C4 Opt SBS 0 500 800 30.75 ± 0.43 36.97 ± 0.18
Opt SBS 180 500 800 BLQ 0.51 ± 0
Opt Dial 0 500 800 BLQ BLQ
Opt Dial 180 500 800 0.91 ± 0.08 0.94 ± 0.15
UFR is constant at rate of 300 ml/hr except for the one condition. *UFR was 250 mL/hr. Sol: Solution; Poly: Polyflux filter; Opt: Optiflux filter; Dial: Dialysate; Vanco:
Mean vancomycin concentration; TG: Mean total gentamicin concentration; BLQ: Below the lower limit of quantification.
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clearance as it pertains to changes in a dialysis prescrip-
tion. This knowledge could be helpful if used in concert
with available clinical data. If drug clearance can be dem-
onstrated in such a model, clinical trials may not be neces-
sary (presuming no active metabolites). In one study, the
reliability of an in vitro model of vancomycin clearance to
predict drug clearance was demonstrated [20]. There have
been few in-vitro studies with other medications such as
intravenous iron sucrose and dextran [21,22]. Pinner et al.
determined that the in vitro method overestimated in vivo
dialysis clearance of vancomycin and gentamicin, 27% and
17%, respectively [13]. However, only one set of dialysis
parameters was studied, which is an important distinction
of that study compared to the present investigation [13].
Conclusion
This study aimed to characterize the clearance of vanco-
mycin and gentamicin and the influence of changes in 3Table 3 Summary of the quantity of vancomycin and gentam
clearance
Condition Filter Sol BFR (mL/min) DFR (mL/min) Va
C1 Poly Dial 400 600 14
C2 Poly Dial 500 800 15
C3 Opt* Dial 400* 600* 13
C4 Opt Dial 500 800 13
UFR is constant at rate of 300 ml/hr except for the one condition. *UFR was 250 ml/hr
Vancomycin concentration; Gent: Total Gentamicin concentration; BLQ: Below the lo
Gentamicin clearance.variables (BFR, DFR and hemodialysis filters) on clear-
ance in a closed loop in vitro dialysis system. Our study
did not detect a difference in the clearance of vanco-
mycin and gentamicin with increasing flow rates and
more efficient hemodialysis filters. The concentra-
tions of vancomycin and gentamicin in the SBS were
undetectable at the conclusion of most sessions. This
reflects nearly 100% clearance of both molecules in
all sessions. The observed differences in the clear-
ance of vancomycin and gentamicin between clinical
studies and this study were likely due to the absence
of protein binding and other volume of distribution
changes not reflected in the in vitro system. Adaptation
of the model to reflect in vivo characteristics may improve
the performance of the system to detect differences
in solute clearance. In addition, this underscores the
importance of clinical pharmacokinetic and pharmacody-
namic studies to validate data obtained from in vitro
studies.icin using the mass balance equation and dialytic
nco (mg) Gent (mg) ClVanc (mL/min) ClGent (mL/min)
7.0 ± 44.7 142.7 ± 20 82.1 58.2
2.9 ± 7.2 142.7 ± 1.02 53.3 43.5
1.0 ± 108.4* 124.0 ± 101.5* 65.3* 56.6*
1.9 ± 12.3 137.0 ± 21.5 47.7 40.6
. Sol: Solution; Poly: Polyflux filter; Opt: Optiflux filter; Dial: Dialysate; Vanco:
wer limit of quantification; ClVanc: Mean Vancomycin Clearance; ClGent: Mean
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